drugset / Trial / NCT02062281
Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults
Phase 4
Completed
2225 enrolled
Jiangsu Province Centers for Disease Control and Prevention
Chengdu Institute of Biological Products Co.,Ltd. · collabShanghai Institute Of Biological Products · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
The 23-valent pneumococcal Polysaccharide vaccine (23vPPV) has been developed for children and adults to prevent pneumococcal diseases such as pneumonia (inflammation of the lungs), meningitis (inflammation of the brain lining), and septicemia (blood poisoning) since 2006 in China. Also, the trivalent influenza vaccine (TIV) is frequently administered to the children and adults. The main objective of this study is to show that both vaccines can safely be administered together without affecting the immune response of protecting against disease.
Timeline
- Start
- 2013-11
- Primary completion
- 2013-12
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Influenza Virus Vaccine | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Pneumovax 23 | Vaccine | 0.5 ml | Intramuscular |